August 11, 2023 02:58 PM EDTUpdated August 12, 01:49 PM
Pharma
FDA+

No­vo Nordisk buck­les down on lob­by­ing ef­forts, inch­ing to­ward CMS cov­er­age of obe­si­ty treat­ments

Lia DeGroot

No­vo Nordisk has spent the sum­mer build­ing out its lob­by­ing team on K Street as part of its ef­forts to get Medicare to cov­er obe­si­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

Biotech VC firm out­lines plans for $100M fund

The drug lob­by's law­suit against the IRA finds a sign of life af­ter ap­peals court rul­ing

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times